8-60741901-C-T
Variant summary
Our verdict is Pathogenic. The variant received 18 ACMG points: 18P and 0B. PVS1PM2PP5_Very_Strong
The NM_017780.4(CHD7):c.469C>T(p.Arg157*) variant causes a stop gained change involving the alteration of a non-conserved nucleotide. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Pathogenic (★★). Variant results in nonsense mediated mRNA decay.
Frequency
Consequence
NM_017780.4 stop_gained
Scores
Clinical Significance
Conservation
Publications
- CHARGE syndromeInheritance: AD Classification: DEFINITIVE, STRONG, SUPPORTIVE Submitted by: Labcorp Genetics (formerly Invitae), Orphanet, PanelApp Australia, Broad Center for Mendelian Genomics, ClinGen, G2P
- hypogonadotropic hypogonadism 5 with or without anosmiaInheritance: AD Classification: STRONG Submitted by: Labcorp Genetics (formerly Invitae)
- hypogonadotropic hypogonadismInheritance: AD Classification: SUPPORTIVE Submitted by: Orphanet
- Kallmann syndromeInheritance: AD Classification: SUPPORTIVE Submitted by: Orphanet
- Omenn syndromeInheritance: AR Classification: SUPPORTIVE Submitted by: Orphanet
Genome browser will be placed here
ACMG classification
Our verdict: Pathogenic. The variant received 18 ACMG points.
Transcripts
RefSeq
| Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | MANE | Protein | UniProt |
|---|---|---|---|---|---|---|---|---|
| CHD7 | NM_017780.4 | c.469C>T | p.Arg157* | stop_gained | Exon 2 of 38 | ENST00000423902.7 | NP_060250.2 |
Ensembl
| Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | TSL | MANE | Protein | Appris | UniProt |
|---|---|---|---|---|---|---|---|---|---|---|
| CHD7 | ENST00000423902.7 | c.469C>T | p.Arg157* | stop_gained | Exon 2 of 38 | 5 | NM_017780.4 | ENSP00000392028.1 |
Frequencies
GnomAD3 genomes Cov.: 32
GnomAD2 exomes AF: 0.00000407 AC: 1AN: 245594 AF XY: 0.00000749 show subpopulations
GnomAD4 exome Data not reliable, filtered out with message: AC0 AF: 0.00 AC: 0AN: 1460796Hom.: 0 Cov.: 32 AF XY: 0.00 AC XY: 0AN XY: 726616
GnomAD4 genome Cov.: 32
ClinVar
Submissions by phenotype
CHARGE syndrome Pathogenic:6
- -
- -
This variant was determined to be pathogenic according to ACMG Guidelines, 2015 [PMID:25741868]. -
ACMG classification criteria: PVS1 very strong, PS4 moderate, PM2 moderate, PM6 strong, PP1 -
This sequence change creates a premature translational stop signal (p.Arg157*) in the CHD7 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in CHD7 are known to be pathogenic (PMID: 22461308, 25077900). The frequency data for this variant in the population databases is considered unreliable, as metrics indicate poor data quality at this position in the gnomAD database. This premature translational stop signal has been observed in individual(s) with CHARGE syndrome (PMID: 15300250, 16155193, 17661815, 20624498, 21158681, 22461308, 23024289, 26538304; Invitae). In at least one individual the variant was observed to be de novo. It has also been observed to segregate with disease in related individuals. ClinVar contains an entry for this variant (Variation ID: 195321). For these reasons, this variant has been classified as Pathogenic. -
PVS1, PS2, PM2 -
not provided Pathogenic:2
- -
Nonsense variant predicted to result in protein truncation or nonsense mediated decay in a gene for which loss-of-function is a known mechanism of disease; Not observed at a significant frequency in large population cohorts (gnomAD); This variant is associated with the following publications: (PMID: 21554267, 21856375, 16155193, 21158681, 22461308, 17661815, 20624498, 21378379, 15300250, 26538304, 23024289) -
not specified Pathogenic:1
- -
Inborn genetic diseases Pathogenic:1
The p.R157* variant (also known as c.469C>T), located in coding exon 1 of the CHD7 gene, results from a C to T substitution at nucleotide position 469. This changes the amino acid from an arginine to a stop codon within coding exon 1. This mutation has been detected in several individuals with CHARGE syndrome diagnoses and in others who only presented with minor diagnostic criteria features (Sohn YB et al. J. Hum. Genet., 2016 Mar;61:235-9). (Vissers LE et al. Nat. Genet., 2004 Sep;36:955-7). (Delahaye A et al. Clin. Genet., 2007 Aug;72:112-21). In addition to the clinical data presented in the literature, this alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay. As such, this alteration is interpreted as a disease-causing mutation. -
CHD7-related disorder Pathogenic:1
The CHD7 c.469C>T variant is predicted to result in premature protein termination (p.Arg157*). This variant has been previously reported in the heterozygous state in several individuals with CHARGE syndrome (see, for example, Vissers et al. 2004. PubMed ID: 15300250, reported as R157X; Sohn et al. 2015. PubMed ID: 26538304). It has been reported as both a de novo variant (Legendre et al. 2012. PubMed ID: 23024289), and an inherited variant characterized by intrafamilial clinical variability (Delahaye et al. 2007. PubMed ID: 17661815). This variant is reported in 0.00090% of alleles in individuals of European (Non-Finnish) descent in gnomAD. Nonsense variants in CHD7 are expected to be pathogenic. This variant is interpreted as pathogenic. -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at